| Literature DB >> 34731762 |
Özlem Akgül1, Elena Lucarini2, Lorenzo Di Cesare Mannelli2, Carla Ghelardini2, Katia D'Ambrosio3, Martina Buonanno3, Simona Maria Monti3, Giuseppina De Simone3, Andrea Angeli4, Claudiu T Supuran4, Fabrizio Carta5.
Abstract
We report a series of compounds 1-17 derived from the antiepileptic drug Sulthiame (SLT) from which both the benzenesulfonamide and the sultam moiety were retained. All compounds were tested in vitro for their inhibition activity against the human (h) Carbonic Anhydrase (CA; EC 4.2.1.1) I, II, VII, IX and XII isoforms. Among the series, derivatives 1 and 11 showed great enhancement of both inhibition potency and selectivity towards the hCA VII isoform, when compared to the reference SLT drug. The binding mode of 11 within the hCA VII active site was deciphered by means of X-ray crystallography and revealed the sultam moiety being exposed to the rim of the active site. In vivo experiments on a model of neuropathic pain induced by oxaliplatin clearly showed 11 being an effective pain relieving agent and therefore worth of further exploitation towards the validation of the hCA VII as new target for the management of neuropathies.Entities:
Keywords: Carbonic anhydrase VII; Neuropathic pain; Sultam
Mesh:
Substances:
Year: 2021 PMID: 34731762 DOI: 10.1016/j.ejmech.2021.113956
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514